BofA upgraded Apellis to Buy from Neutral with a price target of $85, up from $52, following the shares rallying on an encouraging safety update to the Syfovre label.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on APLS:
- Raymond James sticks with ‘Street-high’ Apellis estimate after update
- FDA issues anticipated revised label for Apellis’ Syfovre, says Wedbush
- Apellis director Dunlop sells 24,000 common shares
- Apellis Pharmaceuticals to Host a Fireside Chat at the 6th Annual Evercore ISI HealthCONx Conference
- Apellis price target raised to $49 from $42 at Mizuho